Placebo News and Research

RSS

Arena Pharmaceuticals kicks off APD334 Phase 1 clinical trial for treatment of autoimmune diseases

Arena Pharmaceuticals, Inc. announced today the initiation of dosing in a Phase 1 clinical trial of APD334, a novel oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of autoimmune diseases.

6 Apr 2013

Clinical trial signals new era in treatment of neurodegererative disorders

The initial clinical trial of a novel approach to treating amyotrophic lateral sclerosis - blocking production of a mutant protein that causes an inherited form of the progressive neurodegererative disease - may be a first step towards a new era in the treatment of such disorders.

4 Apr 2013

Reformulated version of anti-HIV gel safe for HIV-negative men and women

A reformulated version of an anti-HIV gel developed for vaginal use was found safe and acceptable by HIV-negative men and women who used it rectally, according to a Phase I clinical trial published today in PLOS ONE.

4 Apr 2013

Researchers confirm effectiveness of spray that improves dry mouth

Researchers from the universities of Granada and Murcia have confirmed the effectiveness of a spray containing 1% malic acid, which greatly improves xerostomy, or dry mouth, caused by anti-depressant drugs.

4 Apr 2013

Study: V710 vaccine does not reduce postoperative Staphylococcus aureus infections

Use of a vaccine to prevent Staphylococcus aureus infections among patients undergoing cardiothoracic surgery did not reduce the rate of serious postoperative S aureus infections compared with placebo and was associated with increased mortality among patients who developed S aureus infections, according to a study in the April 3 issue of JAMA.

3 Apr 2013

Duloxetine drug alleviates pain from chemotherapy

Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April 3 issue of JAMA.

3 Apr 2013

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

Ulcerative colitis (UC) and Crohn’s disease (CD) are both relapsing and remitting chronic diseases of bowel inflammation. By that I mean they flare and physicians try to get the flare under control and try to induce remission. However, despite a number of treatments available, they tend to relapse.

From Takeda 3 Apr 2013

Isis Pharmaceuticals starts ISIS-APOARx Phase 1 clinical study for treatment of atherosclerosis

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 clinical study for ISIS-APOARx, an antisense drug targeting apolipoprotein(a) for the treatment of atherosclerosis.

3 Apr 2013

Biogen acquires TYSABRI stake from Elan

Biogen Idec today announced it has completed its purchase of Elan Corporation's interest in TYSABRI (natalizumab) and has gained full strategic, commercial and decision-making rights to TYSABRI.

3 Apr 2013

First patient dosed in second Phase 2 study with LiRIS for treatment of Interstitial Cystitis

TARIS Biomedical, a specialty pharmaceutical company developing innovative, targeted therapies to treat bladder diseases with high unmet medical need, announced today that it has dosed the first patient in its second Phase 2 clinical study with LiRIS, its novel product candidate, in patients with Interstitial Cystitis.

3 Apr 2013

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer.

2 Apr 2013

Ampio Pharmaceuticals receives FDA IND approval to start clinical trial of Ampion

Ampio Pharmaceuticals, Inc. today announced FDA acceptance of its IND and the treatment of the first fifteen (15) patients in its clinical trial using Ampion™ to treat osteoarthritis of the knee.

2 Apr 2013

New evidence shows older adults with dementia can be taken off antipsychotic medications

Most older adults with dementia can successfully be taken off antipsychotic medications, which have negative side effects and increase the risk of death, finds a new evidence review from The Cochrane Library.

29 Mar 2013

Virginia G. Piper Cancer Center Clinical Trials successfully tests cabozantinib

The FDA has approved a thyroid cancer drug successfully tested at Virginia G. Piper Cancer Center Clinical Trials, a partnership of Scottsdale Healthcare and the Translational Genomics Research Institute.

28 Mar 2013

Smokers trying to quit will have better experience with varenicline, study finds

Smokers have a higher probability of quitting smoking and a better overall cessation experience when taking varenicline compared to bupropion and to placebo - unmedicated assisted smoking cessation -according to a study published in the journal JAMA Psychiatry.

28 Mar 2013

Tecfidera gets FDA approval for adults with relapsing forms of MS

The U.S. Food and Drug Administration today approved Tecfidera (dimethyl fumarate) capsules to treat adults with relapsing forms of multiple sclerosis.

28 Mar 2013

Chelation therapy with drug disodium EDTA reduces risk of heart attack

Although chelation therapy with the drug disodium EDTA has been used for many years with limited evidence of efficacy for the treatment of coronary disease, a randomized trial that included patients with a prior heart attack found that use of a chelation regimen modestly reduced the risk of a composite of adverse cardiovascular outcomes.

27 Mar 2013

Neurocrine Biosciences starts elagolix Phase IIb clinical trial for treatment of uterine fibroids

Neurocrine Biosciences, Inc. today announced that a Phase IIb clinical trial to evaluate elagolix for the treatment of uterine fibroids has been initiated.

27 Mar 2013

FDA clears Soligenix's IND application for SGX942 for treatment of oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company, announced today that the Food and Drug Administration has completed its review and cleared the Investigational New Drug application for SGX942 for the treatment of oral mucositis resulting from radiation and/or chemotherapy treatment in head and neck cancer patients.

27 Mar 2013

Lightlake to present Phase II clinical trial results of opioid antagonist nasal spray at APA Annual Meeting

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing addiction treatments, announced today that a scientific abstract based on results of the Company's Phase II clinical trial of its opioid antagonist nasal spray treatment for patients with Binge Eating Disorder has been accepted for presentation at the American Psychiatric Association Annual Meeting taking place in San Francisco, California, May 18-22, 2013.

27 Mar 2013

Placebo News and Research

Arena Pharmaceuticals kicks off APD334 Phase 1 clinical trial for treatment of autoimmune diseases

Clinical trial signals new era in treatment of neurodegererative disorders

Reformulated version of anti-HIV gel safe for HIV-negative men and women

Researchers confirm effectiveness of spray that improves dry mouth

Study: V710 vaccine does not reduce postoperative Staphylococcus aureus infections

Duloxetine drug alleviates pain from chemotherapy

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

Isis Pharmaceuticals starts ISIS-APOARx Phase 1 clinical study for treatment of atherosclerosis

Biogen acquires TYSABRI stake from Elan

First patient dosed in second Phase 2 study with LiRIS for treatment of Interstitial Cystitis

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

Ampio Pharmaceuticals receives FDA IND approval to start clinical trial of Ampion

New evidence shows older adults with dementia can be taken off antipsychotic medications

Virginia G. Piper Cancer Center Clinical Trials successfully tests cabozantinib

Smokers trying to quit will have better experience with varenicline, study finds

Tecfidera gets FDA approval for adults with relapsing forms of MS

Chelation therapy with drug disodium EDTA reduces risk of heart attack

Neurocrine Biosciences starts elagolix Phase IIb clinical trial for treatment of uterine fibroids

FDA clears Soligenix's IND application for SGX942 for treatment of oral mucositis

Lightlake to present Phase II clinical trial results of opioid antagonist nasal spray at APA Annual Meeting

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News